

ASX: CVB

31 October 2024

CLEANSING NOTICE – SECOND TRANCHE OF PLACEMENT

Melbourne, Australia & Hatfield, Pennsylvania: CurveBeam AI Limited (ASX: CVB “**CurveBeam AI**” or the “**Company**”) today gives notice under section 708(5)(e) of the *Corporations Act 2001* (Cth) (“**Corporations Act**”).

Background

On 1 August 2024, CurveBeam announced that it was undertaking a capital raising comprising a two-tranche institutional placement, (“**Placement**”) and a 1-for-6 accelerated non-renounceable pro-rata entitlement offer. The second tranche of the Placement was subject to shareholder approval, which was received at an Extraordinary General Meeting of the Company on 3 October 2024.

The Company has today issued 11,111,111 new fully paid ordinary shares (“**New Shares**”) at an issue price of \$0.18 per New Share to KP Rx Healthcare Opportunities Fund pursuant to the second tranche of the Placement.

The Company seeks to rely on section 708A of the Corporations Act with respect to the sale of the New Shares issued under the second tranche of the Placement. These New Shares will rank equally with the existing fully paid ordinary shares on issue.

Statements by CurveBeam AI

CurveBeam AI relies on case 1 in section 708A(5) of the Corporations Act and gives notice that it has issued the New Shares under the second tranche of the Placement without disclosure to investors under Part 6D.2 of the Corporations Act.

As at the date of this notice, CurveBeam AI:

- 1 has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company;
- 2 sections 674 and 674A of the Corporations Act; and
- 3 confirms that, there is no information:
 - a. that has been excluded from a continuous disclosure notice given to ASX in accordance with the ASX Listing Rules; and
 - b. that investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
 - i. the assets and liabilities, financial position and performance, profits and losses and prospects of CurveBeam AI; and
 - ii. the rights and liabilities attaching to CurveBeam AI’s securities,

to the extent to which it would be reasonable for investors and their professional advisers to expect to find such information in a disclosure document.

Authorised for release by the Board of Directors.

ENDS

About CurveBeam AI Limited

CurveBeam AI (ASX:CVB) develops, manufactures and sells specialised medical imaging (CT) scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in the management of musculoskeletal conditions. The Company's flagship CT scanner, HiRise™, performs weight bearing CT scans as well as traditional non weight bearing CT scans, providing a range of advantages over the use of traditional CT or MRI devices. CurveBeam AI has more than 70 employees with its corporate office, AI and IP functions located in Melbourne, VIC, Australia and global operations headquarters in Hatfield, Pennsylvania, USA.

For further information go to <https://curvebeamai.com>

Investor / media enquiries

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

Forward-looking statements

This announcement contains certain forward-looking statements. The words 'forecast', 'estimate', 'like', 'anticipate', 'opinion', 'should', 'could', 'may' and other similar expressions are intended to identify future earnings, financial position and performance of CurveBeam AI. You are cautioned not to place undue reliance on these statements. These forward-looking statements are based on estimates, projections and assumptions made by CurveBeam AI about circumstances and events that have not yet taken place. Although due care and attention has been used in the preparation of these statements, such forward-looking statements are based on numerous assumptions regarding CurveBeam AI's present and future business strategies and the political, regulatory and economic environment in which CurveBeam AI will operate in the future and are subject to change without notice. Statements about market and industry trends, which are based on interpretations of current market conditions, may not be reasonable, and are not guarantees or predictions of future performance.